Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer's Disease

Cells. 2023 Aug 21;12(16):2115. doi: 10.3390/cells12162115.

Abstract

Background: Alzheimer's disease (AD) is a neurodegenerative disease that remains uncured. Its pathogenesis is characterized by the formation of β-amyloid (Aβ) plaques. The use of antigen-specific regulatory T cells (Tregs) through adoptive transfer has shown promise for the treatment of many inflammatory diseases, although the effectiveness of polyspecific Tregs is limited. Obtaining a sufficient number of antigen-specific Tregs from patients remains challenging.

Aims and methods: To address this problem, we used an antibody-like single-chain variable fragment from a phage library and subsequently generated a chimeric antigen receptor (CAR) targeting β-amyloid.

Results: The β-amyloid-specific CARs obtained were stimulated by both recombinant and membrane-bound Aβ isolated from the murine brain. The generated CAR-Tregs showed a normal Treg phenotype, were antigen-specific activatable, and had suppressive capacity.

Conclusion: This study highlights the potential of CAR technology to generate antigen-specific Tregs and presents novel approaches for developing functional CARs.

Keywords: Alzheimer’s disease; beta-amyloid; chimeric antigen receptor; regulatory T cells; single-chain fragment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / therapy
  • Amyloid beta-Peptides
  • Animals
  • Mice
  • Neurodegenerative Diseases*
  • Receptors, Chimeric Antigen*
  • Single-Chain Antibodies*

Substances

  • Amyloid beta-Peptides
  • Receptors, Chimeric Antigen
  • Single-Chain Antibodies

Grants and funding

This work was supported by grants from the German Research Foundation (DFG) (HA 6880/2-3), the Government of Canada’s New Frontiers in Research Fund (NFRF), NFRFT-2020-00787, and the European Union’s Horizon 2020 Research and Innovation Program (825392; RESHAPE consortium). This publication was funded by the DFG within the framework of the Open Access Publication Costs Program.